CEO and Founder SolarisRTC LLC Precision Medicine | Biomedical Regulatory Health Science Expert After having been a management team and C suite member responsible for contribution to the overall business strategy and leading pharma services Esther Abels started her own advisory company SolarisRTC in 2023.
 Esther has a background in business strategy, commercialization, bridging R&D, proof of concept, socio / health economics and pivotal clinical validation studies used for registration purposes in different geographies, for both pharma and biotech products. She has over 25 years of regulatory, clinical and quality experience specializing in bringing products to clinical utility. She played a crucial role in getting a De Novo for Whole Slide Imaging devices, i.e., reclassified these devices from the highest risk class III to a moderate risk class II device in USA and getting the first digital pathology algorithms certified under IVDR in Europe. Esther drives efforts for reimbursement in digital pathology and collaborations with different Pathology Associations. She was the president for the Digital Pathology Association (DPA) in 2022, chaired the DPA Regulatory and Standards Taskforce and facilitates FDA collaborations to drive regulatory and standard clarifications for interoperability and computational pathology in the field of digital pathology. Currently she is the chair of the DPA Pharma Taskforce to find general principles around implementing digital pathology to discover and develop new drugs, biomarkers and other tools to accelerate the development pipeline. She is also a co-founder of the Alliance for Digital Pathology, now named Pathology Innovation Collaborative Community where she was co-leading the reimbursement workgroup. Esther holds an MSc in Biomedical Health Science from Radboud University Nijmegen, The Netherlands.